(Q34038836)

English

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

phase II clinical trial

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Eric Lawitz

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Fred F Poordad

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Phillip S Pang

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Robert H Hyland

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Xiao Ding

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Hongmei Mo

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

William T Symonds

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

John G McHutchison

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Fernando E Membreno

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

5 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

383

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

9916

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

515-523

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir for previously untreated chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Exploratory study of oral combination antiviral therapy for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary study of two antiviral agents for hepatitis C genotype 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel therapies for hepatitis C - one pill fits all?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962121-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(13)62121-2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34038836&oldid=1641810775"